Authors: JUNG D GRIFFY K WONG R COLBURN W HULSE J

Citation: D. Jung et al., STEADY-STATE RELATIVE BIOAVAILABILITY OF 3 ORAL GANCICLOVIR DOSAGE REGIMENS DELIVERING 6,000 MG DAY IN PATIENTS WITH HUMAN-IMMUNODEFICIENCY-VIRUS/, Journal of clinical pharmacology, 38(11), 1998, pp. 1021-1024

Authors: JUNG D GRIFFY K DORR A RASCHKE R TARNOWSKI TL HULSE J KATES RE

Citation: D. Jung et al., EFFECT OF HIGH-DOSE ORAL GANCICLOVIR ON DIDANOSINE DISPOSITION IN HUMAN-IMMUNODEFICIENCY-VIRUS (HIV)-POSITIVE PATIENTS, Journal of clinical pharmacology, 38(11), 1998, pp. 1057-1062

Authors: PESCOVITZ MD PRUETT TL GONWA T BROOK B MCGORY R WICKER K GRIFFY K ROBINSON CA JUNG D

Citation: Md. Pescovitz et al., ORAL GANCICLOVIR DOSING IN TRANSPLANT RECIPIENTS AND DIALYSIS PATIENTS BASED ON RENAL-FUNCTION, Transplantation, 66(8), 1998, pp. 1104-1107

Authors: WOLFE EJ MATHUR V TOMLANOVICH S JUNG D WONG R GRIFFY K AWEEKA FT

Citation: Ej. Wolfe et al., PHARMACOKINETICS OF MYCOPHENOLATE MOFETIL AND INTRAVENOUS GANCICLOVIRALONE AND IN COMBINATION IN RENAL-TRANSPLANT RECIPIENTS, Pharmacotherapy, 17(3), 1997, pp. 591-598